Emergent BioSolutions (FRA:ER4) Cyclically Adjusted PB Ratio: (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:ER4 Emergent BioSolutions Inc FRA:ER4
60 GF Score
Price €6.08
GF Value €4.37
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Emergent BioSolutions Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Emergent BioSolutions  (FRA:ER4) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Emergent BioSolutions Cyclically Adjusted PB Ratio Related Terms


Emergent BioSolutions Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Emergent BioSolutions's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emergent BioSolutions Cyclically Adjusted PB Ratio Chart

Emergent BioSolutions Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.23 0.54 0.11 0.37 0.51

Emergent BioSolutions Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.26 0.37 0.51 0.35 0.37

FRA:ER4 vs ELTP, ANIK, AKBA: Cyclically Adjusted PB Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Emergent BioSolutions's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Emergent BioSolutions Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Emergent BioSolutions's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Emergent BioSolutions's Cyclically Adjusted PB Ratio falls into.


FRA:ER4
60GF Score
Emergent BioSolutions Inc FRA:ER4
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Emergent BioSolutions Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Emergent BioSolutions's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Emergent BioSolutions's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=5.821/333.9520*333.9520
=5.821

Current CPI (Jun. 2026) = 333.9520.

Emergent BioSolutions Quarterly Data

Book Value per Share CPI Adj_Book
201609 12.036 241.428 16.649
201612 13.931 241.432 19.270
201703 13.936 243.801 19.089
201706 13.237 244.955 18.046
201709 13.567 246.819 18.356
201712 15.379 246.524 20.833
201803 14.387 249.554 19.253
201806 16.069 251.989 21.296
201809 16.583 252.439 21.938
201812 17.272 251.233 22.959
201903 17.110 254.202 22.478
201906 16.829 256.143 21.941
201909 18.399 256.759 23.931
201912 18.756 256.974 24.374
202003 18.729 258.115 24.232
202006 20.177 257.797 26.137
202009 20.137 260.280 25.837
202012 22.272 260.474 28.555
202103 24.173 264.877 30.477
202106 24.240 271.696 29.794
202109 24.467 274.310 29.787
202112 27.623 278.802 33.087
202203 28.091 287.504 32.629
202206 29.006 296.311 32.691
202209 29.647 296.808 33.357
202212 25.953 296.797 29.202
202303 21.962 301.836 24.299
202306 16.922 305.109 18.522
202309 12.713 307.789 13.794
202312 11.260 306.746 12.259
202403 11.731 312.332 12.543
202406 6.814 314.175 7.243
202409 8.420 315.301 8.918
202412 8.587 315.605 9.086
202503 9.388 319.799 9.803
202506 8.506 322.561 8.806
202509 9.407 324.800 9.672
202512 8.541 324.054 8.802
202603 8.764 330.213 8.863
202606 5.821 333.952 5.821

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Emergent BioSolutions (FRA:ER4) Overvalued in 2026?

Based on GuruFocus' analysis, Emergent BioSolutions stock appears to be overvalued. The current stock price of €6.08 is trading 39.1% above its estimated GF Value™ of €4.37. GuruFocus considers Emergent BioSolutions to be Significantly Overvalued.

Key valuation signals for FRA:ER4:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €4.37 vs. price of €6.08 (39.1% above fair value)
  • GF Score™: 60/100 with 7 warning signs

No single metric tells the full story. See the FRA:ER4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Emergent BioSolutions Business Description

Other Exchanges EBS:USA0IGA:UKER4:Germany
Address 300 Professional Drive, Gaithersburg, MD, USA, 20879
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
60GF Score

Get the complete analysis for FRA:ER4

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.08
Price
€4.37
GF Value